Enliven Therapeutics Inc Stock Price, News & Analysis

Enliven Therapeutics (Nasdaq: ELVN) reported significant progress in Q2 2025, highlighted by positive Phase 1 clinical trial results for ELVN-001 in chronic myeloid leukemia (CML) treatment. The trial demonstrated a 47% cumulative MMR rate, with 32% of patients achieving MMR by 24 weeks, surpassing historical data from competitor treatments.

The company strengthened its financial position through a $230 million public offering, ending Q2 with $490.5 million in cash and equivalents, extending runway into H1 2029. Quarterly financials showed R&D expenses of $21.5 million and a net loss of $25.3 million. Enliven plans to initiate a Phase 3 pivotal trial in 2026.

Enliven Therapeutics (Nasdaq: ELVN) has successfully closed its public offering, raising approximately $230 million in gross proceeds. The offering included 9,920,987 shares of common stock at $19.66 per share, including the full exercise of the underwriters' option for 1,526,250 additional shares. Additionally, the company issued pre-funded warrants to purchase 1,780,263 shares at $19.659 per warrant. The offering was managed by Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho as joint book-running managers, with LifeSci Capital acting as lead manager. The securities were offered through a Registration Statement on Form S-3 and related filings with the SEC.

Enliven Therapeutics (ELVN) has announced the pricing of its public offering, consisting of 8,394,737 shares of common stock at $19.66 per share and pre-funded warrants for up to 1,780,263 shares at $19.659 per warrant. The gross proceeds are expected to be approximately $200 million before deducting expenses. The offering is set to close around June 16, 2025. The company has granted underwriters a 30-day option to purchase up to an additional 1,526,250 shares. Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are serving as joint book-running managers, with LifeSci Capital acting as lead manager for the offering.

Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The company will also grant underwriters a 30-day option to purchase up to an additional $30 million in common stock. The offering is being managed by joint book-runners Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho, with LifeSci Capital as lead manager. The offering will be made through a Registration Statement on Form S-3 and is subject to market conditions and regulatory approval.

Enliven Therapeutics (NASDAQ: ELVN) reported positive Phase 1 data for ELVN-001 in chronic myeloid leukemia (CML) at EHA 2025. The trial showed a 47% cumulative MMR rate by 24 weeks, with 32% achieving and 100% maintaining MMR. Among 90 enrolled patients with median treatment of 29 weeks, 67% received three or more prior TKIs. ELVN-001 demonstrated favorable safety with only 3.4% dose reductions and 4.6% discontinuations due to adverse events. The drug showed promising efficacy in heavily pretreated patients, including those resistant to prior therapies, with MMR rates comparing favorably to historical data. The pharmacokinetic profile supports once-daily dosing, and no maximum tolerated dose was reached. Enliven plans to initiate a head-to-head Phase 3 pivotal trial in 2026.

Enliven Therapeutics (NASDAQ: ELVN), a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, has announced its participation in three major upcoming investor conferences in May and June 2025:

• TD Cowen's 6th Annual Oncology Innovation Summit on May 27, 2025, at 1:00 p.m. ET
• Jefferies Global Healthcare Conference on June 4, 2025, at 4:20 p.m. ET
• Goldman Sachs Annual Global Healthcare Conference on June 10, 2025, at 4:00 p.m. ET

All presentations will be in fireside chat format and will be webcast live through the company's investor relations website, with recordings available for 90 days after each event.

Enliven Therapeutics (NASDAQ: ELVN) reported Q1 2025 financial results and provided updates on its clinical programs. The company's lead drug ELVN-001, a BCR::ABL kinase inhibitor for chronic myeloid leukemia (CML), showed promising results in the Phase 1 ENABLE trial. Key findings include a 44% cumulative MMR rate (16 of 36 patients) by 24 weeks, with favorable safety and tolerability profiles. The company maintains a strong financial position with $289.6 million in cash and equivalents, providing runway into late 2027. Q1 2025 resulted in a net loss of $28.5 million. Notably, Enliven plans to deprioritize its ELVN-002 program to focus on advancing ELVN-001 towards a potential pivotal trial in 2026. Updated ELVN-001 trial data will be presented at the EHA 2025 Congress in June.

Enliven Therapeutics (NASDAQ: ELVN) reported updated positive data from its Phase 1 ENABLE clinical trial of ELVN-001 in chronic myeloid leukemia (CML) patients. Key highlights include:

The trial showed a 44% cumulative major molecular response (MMR) rate (16 of 36 patients) by 24 weeks, with 26% achieving and 100% maintaining MMR. The study enrolled 74 heavily pretreated patients, with 66% having received three or more prior tyrosine kinase inhibitors (TKIs).

ELVN-001, a selective BCR::ABL1 kinase inhibitor, demonstrated strong efficacy in resistant cases, with 40% of TKI-resistant patients achieving MMR. The drug showed a favorable safety profile across all doses, with low rates of dose interruptions (<10%) and reductions (<5%). The results will be presented at the EHA 2025 Congress in Milan.

Enliven Therapeutics (Nasdaq: ELVN) has announced it will present five posters at the 2025 AACR Annual Meeting in Chicago from April 25-30, 2025. The presentations will showcase their pipeline of small molecule therapeutics, including:

- ELVN-002: A selective HER2 inhibitor with potential enhanced efficacy in combination with antibody-drug conjugates
- ELVN-001: A selective ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia treatment
- ELV-3111: A type 1 pan-RAF inhibitor for NRAS and BRAF mutant cancers

The presentations will cover pharmacokinetics, drug resistance mechanisms, and combination therapy approaches. All posters will be presented on April 29, 2025, across different sessions and locations at the conference.